Beth M. Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO

Ailawadhi and Faiman discuss the rationale for efforts to bring isatuximab on-body injectors into the clinic for patients with multiple myeloma.

Xavier Leleu, MD, PhD, and Beth Faiman, PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO, discuss key data from the phase 3 IRAKLIA study.

Closing out their program on multiple myeloma, expert panelists consider the role of holistic and multidisciplinary care when managing patients within the current paradigm.

Continuing its discussion on clinical trials in multiple myeloma, the panel emphasizes the impact that data may have on the real-world treatment landscape.

Key opinion leaders in multiple myeloma management elucidate the value of clinical trials and share enthusiasm for improving enrollment when possible.

A focused discussion on the regulatory aspects of drug testing and approval, globally, with respect to the setting of multiple myeloma management.

Expert panelists consider best methods in educating patients on their options for therapy following a diagnosis of multiple myeloma.

Comprehensive insight to disparities that may impact a patient’s access to therapy for multiple myeloma and how these may be overcome.

Panelists share a brief discussion on the current treatment armamentarium available to patients with newly diagnosed multiple myeloma.

Experts in multiple myeloma management consider essential tests that aid in the diagnosis and treatment of newly presenting patients.

Shared insight from key opinion leaders on educational resources made available to physicians and patients, respectively, regarding multiple myeloma management.

Opening its discussion on key unmet needs in multiple myeloma management, a panel of experts discuss key challenges faced when diagnosing patients with multiple myeloma and review the impact of having a multidisciplinary care team.